Decompensated alcohol related liver disease: Acute management

BMJ (Online)

Volumn 352, Issue , 2016, Pages

  McPherson, Stuart ^a,b   Lucey, Michael R ^c   Moriarty, Kieran J ^d  

^a FREEMAN HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d ROYAL BOLTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL;

ALCOHOL CONSUMPTION; ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; ALCOHOL WITHDRAWAL; ASCITES; BACTERIAL PERITONITIS; DECOMPENSATED ALCOHOL RELATED LIVER DISEASE; DISEASE COURSE; GASTROINTESTINAL HEMORRHAGE; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; INTENSIVE CARE; KIDNEY INJURY; NUTRITION; PEPTOCLOSTRIDIUM DIFFICILE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REVIEW; ACUTE KIDNEY INJURY; ALCOHOLISM; BACTERIAL INFECTIONS; COMPLICATION; DISEASE MANAGEMENT; HEPATITIS, ALCOHOLIC; LIVER CIRRHOSIS, ALCOHOLIC; LIVER DISEASES, ALCOHOLIC; MORTALITY;

ACUTE KIDNEY INJURY; ALCOHOLISM; ASCITES; BACTERIAL INFECTIONS; DISEASE MANAGEMENT; HEPATITIS, ALCOHOLIC; HUMANS; LIVER CIRRHOSIS, ALCOHOLIC; LIVER DISEASES, ALCOHOLIC;

EID: 84960086254     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.i124     Document Type: Review

References (69)

1. European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 2012;57:399-420. doi:10.1016/j.jhep.2012.04.004. 22633836.
2. Teli MR, Day CP, Burt AD, Bennett MK, James OF. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 1995;346:987-90. doi:10.1016/ S0140-6736(95)91685-7. 7475591.
3. Ratib S, Fleming KM, Crooks CJ, Walker AJ, West J. Causes of death in people with liver cirrhosis in England compared with the general population: a population-based cohort study. Am J Gastroenterol 2015;110:1149-58. doi:10.1038/ajg.2015.191. 26169512.
4. Williams R, Aspinall R, Bellis M, et al. Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet 2014;384:1953-97. doi:10.1016/S0140-6736(14)61838-9. 25433429.
5. Thomson SJ, Westlake S, Rahman TM, et al. Chronic liver disease-an increasing problem: a study of hospital admission and mortality rates in England, 1979-2005, with particular reference to alcoholic liver disease. Alcohol Alcohol 2008;43:416-22. doi:10.1093/alcalc/agn020. 18385412.
6. British Society of Gastroenterology. A time to act: improving health and outcomes in liver disease. The national plan for liver services. BSG, 2009:1-52.
7. National Condidential Enquiry into Patient Outcome and Death (UK). Measuring the units-a review of patients who died with alcohol related liver disease. NCEPOD, 2013: 1-25.
8. Moreau R, Jalan R, Gines P, et alAcute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013; 144:1426-37.
9. Bernal W, Jalan R, Quaglia A, Simpson K, Wendon J, Burroughs A. Acute-on-chronic liver failure. Lancet 2015;386:1576-87. doi:10.1016/S0140-6736(15)00309-8. 26423181.
10. McPherson S, Dyson J, Austin A, et al. Response to the NCEPOD report: development of a care bundle for patients admitted with decompensated cirrhosis-the first 24h Frontline. Gastoenterology 2016;7:16-23.
11. Fernández J, Gustot T. Management of bacterial infections in cirrhosis. J Hepatol 2012;56(Suppl 1):S1-12. doi:10.1016/S0168-8278(12)60002-6. 22300459.
12. Jalan R, Fernandez J, Wiest R, et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol 2014;60:1310-24. doi:10.1016/ j.jhep.2014.01.024. 24530646.
13. Arvaniti V, D'Amico G, Fede G, et alInfections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010;139:1246-56.
14. Fernández J, Navasa M, Gómez J, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002;35:140-8. doi:10.1053/jhep.2002.30082. 11786970.
15. O'Leary JG, Reddy KR, Wong F, et alLong-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. Clin Gastroenterol Hepatol 2015;13:753-9.
16. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010;53:397-417. doi:10.1016/j.jhep.2010.05.004. 20633946.
17. Ginès P, Fernández J, Durand F, Saliba F. Management of critically-ill cirrhotic patients. J Hepatol 2012;56(Suppl 1):S13-24. doi:10.1016/S0168-8278(12)60003-8. 22300462.
18. Chinnock B, Afarian H, Minnigan H, Butler J, Hendey GW. Physician clinical impression does not rule out spontaneous bacterial peritonitis in patients undergoing emergency department paracentesis. Ann Emerg Med 2008;52:268-73. doi:10.1016/j.annemergmed.2008.02.016. 18433932.
19. Piano S, Fasolato S, Salinas F, et al. The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: results of a randomized, controlled clinical trial. Hepatology 2015, published online 18 June.
20. Rimola A, García-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol 2000;32:142-53. doi:10.1016/S0168-8278(00)80201-9. 10673079.
21. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403-9. doi:10.1056/NEJM199908053410603. 10432325.
22. Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med 2009;360:2758-69. doi:10.1056/NEJMra0805786. 19553649.
23. Hardy T, Wells C, Kendrick S, et al. White cell count and platelet count associate with histological alcoholic hepatitis in jaundiced harmful drinkers. BMC Gastroenterol 2013;13:55. doi:10.1186/1471-230X-13-55. 23530737.
24. Mathurin P, Bataller R. Trends in the management and burden of alcoholic liver disease. J Hepatol 2015;62(Suppl):S38-46. doi:10.1016/j.jhep.2015.03.006. 25920088.
25. Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr, , Mezey E, White RI Jr. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978;75:193-9.352788.
26. Forrest EH, Evans CD, Stewart S, et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 2005;54:1174-9. doi:10.1136/gut.2004.050781. 16009691.
27. Srikureja W, Kyulo NL, Runyon BA, Hu KQ. MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis. J Hepatol 2005;42:700-6. doi:10.1016/j.jhep.2004.12.022. 15826720.
28. Mathurin P, O'Grady J, Carithers RL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2011;60:255-60. doi:10.1136/gut.2010.224097. 20940288.
29. O'Shea RS, Dasarathy S, McCullough AJ. Practice Guideline Committee of the American Association for the Study of Liver Diseases Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology 2010;51:307-28. doi:10.1002/hep.23258. 20034030.
30. National Institute for Health and Care Excellence. Alcohol use disorders: diagnosis and clinical management of alcohol-related physical complications. (Clinical guideline 100.) www.nice.org.uk/guidance.nice.org.uk/CG100.
31. Rambaldi A, Saconato HH, Christensen E, Thorlund K, Wetterslev J, Gluud C. Systematic review: glucocorticosteroids for alcoholic hepatitis-a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther 2008;27:1167-78. doi:10.1111/j.1365-2036.2008.03685. x. 18363896.
32. Thursz MR, Richardson P, Allison M, et al. STOPAH Trial. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med 2015;372:1619-28. doi:10.1056/ NEJMoa1412278. 25901427.
33. Singh S, Murad MH, Chandar AK, et alComparative effectiveness of pharmacological interventions for severe alcoholic hepatitis: a systematic review and network meta-analysis. Gastroenterology 2015;149:958-70.
34. Louvet A, Naveau S, Abdelnour M, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 2007;45:1348-54. doi:10.1002/hep.21607. 17518367.
35. Louvet A, Wartel F, Castel H, et al. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology 2009;137:541-8. doi:10.1053/j.gastro.2009.04.062. 19445945.
36. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:1637-48. doi:10.1053/gast.2000.20189. 11113085.
37. Park SH, Kim DJ, Kim YS, et al. Korean Association for the Study of the Liver (KASL)-Alcohol Related Problems Study Group. Pentoxifylline vs corticosteroid to treat severe alcoholic hepatitis: a randomised, non-inferiority, open trial. J Hepatol 2014;61:792-8. doi:10.1016/j.jhep.2014.05.014. 24845609.
38. Mathurin P, Louvet A, Duhamel A, et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA 2013;310:1033-41. doi:10.1001/jama.2013.276300. 24026598.
39. Nguyen-Khac E, Thevenot T, Piquet MA, et al. AAH-NAC Study Group. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med 2011;365:1781-9. doi: 10.1056/NEJMoa1101214. 22070475.
40. Singh V, Sharma AK, Narasimhan RL, Bhalla A, Sharma N, Sharma R. Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study. Am J Gastroenterol 2014;109:1417-23. doi:10.1038/ajg.2014.154. 24935272.
41. Mathurin P, Moreno C, Samuel D, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011;365:1790-800. doi:10.1056/NEJMoa1105703. 22070476.
42. Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology 2008;48:2064-77. doi:10.1002/hep.22605. 19003880.
43. Angeli P, Gines P, Wong F, et al. International Club of Ascites. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut 2015;64:531-7. doi:10.1136/gutjnl-2014- 308874. 25631669.
44. Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007;56:1310-8.17389705.
45. Angeli P, Sanyal A, Moller S, et al. International Club of Ascites. Current limits and future challenges in the management of renal dysfunction in patients with cirrhosis: report from the International Club of Ascites. Liver Int 2013;33:16-23. doi:10.1111/j.1478-3231.2012.02807.x. 22507181.
46. National Institute for Health and Clinical Excellence. Intravenous fluid therapy in adults in hospital. (Clinical guideline 174.) 2013. www.nice.org.uk/guidance.nice.org.uk/CG174.
47. Gluud LL, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010;51:576-84. doi:10.1002/hep.23286. 19885875.
48. Cavallin M, Kamath PS, Merli M, et al. Italian Association for the Study of the Liver Study Group on Hepatorenal Syndrome. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial. Hepatology 2015;62:567-74. doi:10.1002/hep.27709. 25644760.
49. Gordon FD. Ascites. Clin Liver Dis 2012;16:285-99. doi:10.1016/j.cld.2012.03.004. 22541699.
50. Runyon BA, Committee APG. Management of adult patients with ascites due to cirrhosis: an update in 2012. 2012:1-92. www.aasld.org/sites/default/files/guideline-documents/141020-Guideline-Ascites-4UFb-2015.pdf
51. Ginés P, Arroyo V, Quintero E, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology 1987;93:234-41.3297907.
52. National Institute for Health and Care Excellence. Acute upper gastrointestinal bleeding. (Clinical guideline 141.) 2012. www.nice.org.uk/guidance.nice.org.uk/CG141.
53. Tripathi D, Stanley AJ, Hayes PC, et al. UK guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut 2015;64:1680-704.25887380.
54. De Franchis R. Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 2015;63:743-52. doi:10.1016/j.jhep.2015.05.022. 26047908.
55. Ellul MA, Gholkar SA, Cross TJ. Hepatic encephalopathy due to liver cirrhosis. BMJ 2015;351:h4187. doi:10.1136/bmj.h4187. 26265724.
56. Maharshi S, Sharma BC, Srivastava S. Malnutrition in cirrhosis increases morbidity and mortality. J Gastroenterol Hepatol 2015;30:1507-13. doi:10.1111/jgh.12999. 25974421.
57. Rossi RE, Conte D, Massironi S. Diagnosis and treatment of nutritional deficiencies in alcoholic liver disease: Overview of available evidence and open issues. Dig Liver Dis 2015;47:819-25. doi:10.1016/j.dld.2015.05.021. 26164399.
58. Singal AK, Charlton MR. Nutrition in alcoholic liver disease. Clin Liver Dis 2012;16:805-26. doi:10.1016/j.cld.2012.08.009. 23101983.
59. Plauth M, Cabré E, Riggio O, et al. DGEM (German Society for Nutritional Medicine) ESPEN (European Society for Parenteral and Enteral Nutrition). ESPEN Guidelines on enteral nutrition: liver disease. Clin Nutr 2006;25:285-94. doi:10.1016/j. clnu.2006.01.018. 16707194.
60. Moriarty KJ, Cassidy P, Dalton D, et al. Alcohol-related disease. Meeting the challenge of improved quality of care and better use of resources. A joint position paper on behalf of the British Society of Gastroenterology, Alcohol Health Alliance UK & British Association for Study of the Liver. 2010: www.bsg.org.uk/images/stories/docs/clinical/publications/ bsg-alc-disease-10.pdf.
61. Teams AC. reducing acute hospital admissions and improving quality of care. NICE quality and productivity: proven case study 2014. http://arms.evidence.nhs.uk/resources/qipp/ 29420/attachment.
62. Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict 1989;84:1353-7. doi:10.1111/j.1360-0443.1989.tb00737.x. 2597811.
63. National Institute for Health and Care Excellence. Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence: (Clinical guideline 115.) 2011. www.nice.org.uk/guidance.nice.org.uk/CG115.
64. Day E, Copello A, Hull M. Assessment and management of alcohol use disorders. BMJ 2015;350:h715. doi:10.1136/bmj.h715. 25698774.
65. McPhail MJ, Shawcross DL, Abeles RD, et alIncreased survival for patients with cirrhosis and organ failure in liver intensive care and validation of the Chronic Liver Failure-Sequential Organ Failure Scoring System. Clin Gastroenterol Hepatol 2015;13 :1353-60.
66. Cholongitas E, Betrosian A, Senzolo M, et al. Prognostic models in cirrhotics admitted to intensive care units better predict outcome when assessed at 48 h after admission. J Gastroenterol Hepatol 2008;23:1223-7. doi:10.1111/j.1440-1746.2007.05269.x. 18086109.
67. Masson S, Emmerson I, Henderson E, et al. Clinical but not histological factors predict long-term prognosis in patients with histologically advanced non-decompensated alcoholic liver disease. Liver Int 2014;34:235-42. doi:10.1111/liv.12242. 23834275.
68. Boyd K, Kimbell B, Murray S, et al. A "good death" with irreversible liver disease: talking with patients and families about deteriorating health and dying. Clin Liver Dis 2015;6:15-8doi:10.1002/cld.479.
69. Volk ML. Hospital readmissions for decompensated cirrhosis. Clin Liver Dis 2014;4:138-40doi:10.1002/cld.420.